Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionTritonpoint Wealth, Llc
Latest Disclosed Ownership612 shares
Latest Disclosed Value $ 273,282
Tritonpoint Wealth, Llc reports 18.38% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On April 21, 2026 - Tritonpoint Wealth, Llc filed a 13F-HR form disclosing ownership of 612 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $273,282 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 20, 2026 disclosing 517 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 18.38% during the quarter. The current value of the position is $273,460 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-21 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 612 95 18.38 273 16.67 0.0293
2026-01-20 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 517 -31 -5.66 234 9.35 0.0238
2025-10-15 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 548 -53 -8.82 215 -19.85 0.0184
2025-07-17 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 601 -3 -0.50 268 -8.56 0.0248
2025-04-16 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 604 83 15.93 293 39.71 0.0279
2025-01-24 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 521 -7 -1.33 210 -14.34 0.0190
2024-10-28 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 528 35 7.10 244 6.09 0.0223
2024-08-12 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 493 493 231 0.0222
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.